HOME >> BIOLOGY >> NEWS
Honeybee gene find ends 150-year search

The genetic signal that makes a honeybee male or female has been identified by researchers in Germany, the U.S. and Norway. The finding, published in the August 22 issue of the journal Cell, shows how male bees can have no father, a scientific puzzle going back over 150 years and the explanation for why bees, ants and wasps often form colonial societies. It could also make it easier to breed honeybees.

The researchers found that female bees have two different versions of a gene called csd, one from each parent, that form an active protein that triggers female development. Unfertilized eggs, which have only one copy of csd from the mother, default to being males.

In 1845, a Polish parish priest called Johann Dzierzon proposed that male bees have no fathers: They develop from unfertilized eggs, while females grow from fertilized eggs. Later work showed that Dzierzon was right. Male bees have half as many genes (haploid) as females, which get a set of genes from each parent (diploid). About one-fifth of animal species including all ants, bees and wasps use a similar haplodiploid system of sex determination, but the actual genes and mechanisms involved are not well understood.

Martin Beye and Martin Hasselmann from the Martin Luther University of Halle/Wittenberg, Germany, and Robert Page and Kim Fondrk at the University of California, Davis, isolated a honeybee gene called complementary sex determiner, or csd. Csd exists in 19 alternative versions, or alleles, Page said. Female bees have two copies of csd which are always different alleles. Males have only one copy.

The researchers worked out the DNA sequence of four csd alleles and found that they were highly variable. But the same alleles were found in both males and females, showing that there are no alleles for "maleness" or "femaleness."

Studies on developing eggs showed that in both males and females, the csd gene becomes active about 12 hours after eggs are laid and remain
'"/>

Contact: Andy Fell
ahfell@ucdavis.edu
530-752-4533
University of California - Davis
21-Aug-2003


Page: 1 2 3

Related biology news :

1. USDA establishes Honeybee Genetics and IPM Center
2. Summer Science: Where Have All The Honeybees Gone? UD Bee Guy Asks Why--From America To The Amazon
3. Careful Honeybee Breeding Combats Tracheal Mite Pests
4. Honeybees In The Wild Nearly Gone In North America
5. 150-year global ice record reveals major warming trend
6. Leader in cancer treatment and prevention research honored
7. Landmark agreement between Samoa and UC Berkeley could help search for AIDS cure
8. Researchers determine genetic cause of Timothy syndrome
9. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative
10. Scientists to prototype cyberinfrastructure for research and education access to ocean observatories
11. Belgian researchers explore revolutionary approach to angiogenesis

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Honeybee gene find ends year search

(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... in Europe and the United States and plenary talks ... planned for SPIE Optics + Optoelectronics next ... over 700 technical presentations in 17 conferences alongside a ... for optics and photonics , the event will run ...
(Date:3/30/2015)... 30, 2015  Naldemedine, an investigational peripherally acting ... & Co., Ltd., met its primary and secondary ... for the treatment of opioid-induced constipation (OIC) in ... therapy. Study results showed that naldemedine (0.2 mg ... frequency of spontaneous bowel movement (SBM) compared with ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: